Furosemida Fecofar

Quick links to important sections

Furosemida Fecofar

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Furosemida Fecofar

Property Description
Active ingredient Furosemide (INN)
Form Oral Tablet
Pharmacological class Diuretic (Loop Diuretic)
Common purpose Removal of excess fluid (water and salt)
Origin Synthetic (Chemically produced)

What Type of Medicine is Furosemida Fecofar?

Furosemida Fecofar is a specific brand of medicine whose active ingredient is Furosemide. The product is typically supplied as an oral tablet and is classified as a prescription-only (Rx) medication. Pharmacologically, Furosemide is recognized as a Loop Diuretic, a potent class of “water pills” used for its effectiveness in promoting diuresis. The medicine is a synthetic compound, chemically produced, and is provided as a single-ingredient preparation.

The classification of Furosemide as a Loop Diuretic reflects its action in inhibiting the reabsorption of sodium and chloride in the kidney. This designation signifies its strong and rapid fluid-removing capacity, a feature characteristic of this diuretic category. While numerous generic versions of Furosemide exist, Furosemida Fecofar ensures a consistent tablet formulation containing the essential diuretic compound.


What is the General Purpose of This Medicine?

Its general purpose is to help the body effectively remove excess salt and water by significantly increasing the amount of urine produced. This action directly addresses the problem of fluid retention. By achieving this rapid fluid balance, the medicine helps manage conditions where the body retains too much fluid, such as unwanted fluid retention (edema).

Its classification as a Loop Diuretic directly reflects its capacity for a strong, quick effect. The key benefit is its high efficacy in achieving a negative fluid balance. This ability to manage fluid volume is the foundational therapeutic goal of the active ingredient, Furosemide.

What side effects are possible with Furosemida Fecofar?

Possible Side Effects and Safety Information

The safety profile of Furosemida Fecofar is primarily defined by its effects on fluid and electrolyte balance, alongside the potential for rare, serious systemic reactions. This information summarizes the adverse reactions and limitations documented in official government regulatory sources.


Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency as reported in regulatory documents:

Classification Examples of Reactions
Very Common Electrolyte disturbances, dehydration, hypovolemia, increased creatinine and urea levels
Common Hyponatremia (low sodium), hypokalemia (low potassium), hyperuricemia, hepatic encephalopathy in patients with pre-existing liver failure
Uncommon Hearing disorders, nausea, pruritus (itching), blistering skin reactions
Rare Vasculitis, acute interstitial nephritis, tinnitus (ringing in ears), severe anaphylactic reactions, blood dyscrasias (e.g., agranulocytosis)
Very Rare Pancreatitis, cholestasis, aplastic anemia

Serious and Clinically Significant Risks

Serious Adverse Reactions include severe fluid and electrolyte imbalances that can lead to dangerously low blood volume (hypovolemia) or hepatic coma. Other severe risks are ototoxicity (hearing damage, potentially irreversible, and tinnitus) and severe, sometimes life-threatening, skin reactions (e.g., Stevens-Johnson Syndrome). Blood and lymphatic system disorders, such as aplastic anemia and agranulocytosis, are also documented as rare but serious concerns.

Safety Restrictions and Monitoring

Regulatory documents emphasize that the risk of ototoxicity is heightened with very high doses, rapid intravenous administration, or in patients with severe kidney impairment. The medicine is contraindicated (must not be used) in patients with anuria (inability to pass urine) that does not respond to treatment, and in conditions involving severe fluid or electrolyte depletion. Special caution is warranted in elderly patients, who are more susceptible to complications from fluid loss, and in premature infants, due to the risk of kidney stone formation (nephrocalcinosis).

Overdose and Emergency Response

The official regulatory documents state that Furosemide overdosage results from an exaggerated version of its intended effect, leading to profound diuresis and rapid fluid volume depletion. The documented clinical manifestations are severe dehydration, significant hypovolemia, and marked hypotension. This can progress to severe outcomes, including circulatory collapse, which is a life-threatening emergency demanding immediate action.

Overdose also presents with critical electrolyte imbalance, specifically hypokalemia, hyponatremia, and hypochloremic alkalosis, and may cause azotemia. Certain patients face enhanced risks: elderly patients face an increased risk of vascular thrombosis and embolism, and patients with pre-existing liver cirrhosis may rapidly precipitate hepatic coma due to sudden fluid shifts.

Required Emergency Action

Immediate medical attention is required when overdosage is suspected or any severe manifestations occur, such as circulatory collapse. The treatment described in regulatory labels is strictly supportive management, focusing entirely on the prompt replacement of excessive fluid and electrolyte losses to correct the imbalances. It is officially stated that no specific antidote is known for Furosemide overdosage. Frequent monitoring of serum electrolytes and blood pressure is required until the condition is stabilized.

Therapeutic Uses of Furosemida Fecofar

Main Uses and Clinical Applications

Furosemida Fecofar is a diuretic medication primarily used to manage fluid retention and various forms of hypertension. It belongs to a class of drugs known as loop diuretics, which act on the kidneys to increase the excretion of water and salts.

Management of Edema

The primary application of this medication is the treatment of edema, a condition characterized by an excessive accumulation of fluid in the body's tissues. This accumulation is often associated with specific underlying medical conditions:

  • Congestive Heart Failure: It helps reduce the fluid buildup that occurs when the heart cannot pump blood efficiently, which can lead to swelling in the legs, ankles, and lungs.
  • Renal Disease: In cases of kidney dysfunction, the medication assists the body in eliminating excess fluid that the kidneys are unable to process normally.
  • Hepatic Cirrhosis: It is used to manage ascites (fluid accumulation in the abdominal cavity) and peripheral edema resulting from liver disease.

Treatment of Hypertension

Furosemida Fecofar is also utilized in the management of high blood pressure (hypertension). It can be used as a standalone treatment or in combination with other antihypertensive agents. By reducing the total volume of fluid circulating within the blood vessels, it helps lower the pressure exerted against arterial walls.

Key Benefits

The therapeutic benefits of this medication center on its ability to rapidly and effectively promote diuresis.

Fluid Balance Regulation

By facilitating the removal of excess sodium and chloride through urine, the medication helps restore a more manageable fluid balance within the body. This reduction in systemic fluid volume can alleviate the physical discomfort and complications associated with swelling and internal pressure.

Support for Cardiovascular and Pulmonary Function

In patients with heart failure, the reduction of fluid volume decreases the workload on the heart. Furthermore, by addressing fluid accumulation in the lungs (pulmonary edema), the medication can help improve respiratory function and ease of breathing.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Profile for Furosemida Fecofar

Furosemida Fecofar (Furosemide) eligibility is strictly defined by regulatory documents, distinguishing between populations approved for use, those who require conditional use, and those for whom the medicine is contraindicated.

Contraindications (Must Not Use)

The medicine is absolutely contraindicated for patients with anuria (inability to pass urine) and those with a known hypersensitivity (allergy) to Furosemide. Use is also prohibited in patients with hypovolemia or dehydration, severe hypokalaemia or hyponatraemia, and those in a comatose state due to hepatic encephalopathy.

Conditional Use and Restrictions

Population / Condition Regulatory Status
Breastfeeding Women Contraindicated; excreted in human milk.
Older Adults (Geriatrics) Requires caution due to increased risk of dehydration and vascular complications.
Urinary Outflow Obstruction Requires careful monitoring due to the risk of acute urinary retention.
Pregnancy Not suitable for routine treatment; use is restricted to short periods after review.

Furosemide is approved for adults and pediatric patients to treat edema associated with conditions like congestive heart failure, liver cirrhosis, and renal disease. Specific caution is required for infants due to the risk of nephrocalcinosis.

What should I know about interactions with other medicines?

The official interaction profile for Furosemida Fecofar (Furosemide) identifies several documented interactions, primarily categorized by risks of additive toxicity, altered drug exposure, and enhanced electrolyte disturbances, as detailed in regulatory labeling.

Interaction Type Interacting Substance/Class Regulatory Outcome/Restriction
Contraindicated Combination Ethacrynic acid Strictly contraindicated due to the potential for amplified ototoxicity (hearing damage).
Additive Organ Toxicity Aminoglycoside Antibiotics (e.g., Gentamicin), Cisplatin Increased risk of ototoxicity and/or nephrotoxicity; combination should be avoided except in specific circumstances.
Exposure/Clearance Alteration Lithium Furosemide reduces the renal clearance of Lithium, leading to a high documented risk of lithium toxicity.
Sucralfate Decreases Furosemide's intestinal absorption; administration must be separated by at least two hours.
Phenytoin Reduces the bioavailability of Furosemide, leading to lower plasma concentrations.
Pharmacodynamic Effects NSAIDs (e.g., Indomethacin) May antagonize the diuretic and antihypertensive effect of Furosemide.
Cardiac Glycosides (e.g., Digoxin) Furosemide-induced low potassium (hypokalaemia) may increase the toxicity of cardiac glycosides.
ACE Inhibitors / ARBs Risk of severe hypotension and potential deterioration of renal function.

Co-administration with Corticosteroids or large quantities of Licorice is officially associated with an enhanced risk of potassium loss.

Mechanism of Action

Targeted Inhibition of the Renal Co-transporter

Furosemide's action is defined by the direct blockade of the Na^+- K^+- 2Cl^- co-transporter (NKCC2) located on the luminal membrane of the thick ascending limb of the Loop of Henle. This interaction stops the reabsorption of sodium, potassium, and chloride ions from the filtering fluid back into the bloodstream, which initiates a mechanistic cascade.

Disruption of Renal Fluid Modulation

The retention of these solutes within the renal tubule prevents the normal creation of the medullary osmotic gradient. This disruption limits the driving osmotic force necessary for subsequent water reabsorption in the collecting ducts, leading to the sustained retention of water within the tubule. This mechanism contributes to diuresis (increased fluid excretion) as a primary physiological effect.

Systemic Fluid and Electrolyte Modulation

Salt and water excretion results in a decrease in circulating fluid volume. This mechanistic domain influences downstream electrolyte balance by increasing the delivery of sodium to the distal nephron. This action causes a subsequent flow-dependent exchange of Na^+ for K^+, resulting in secondary modulation of other cation excretion pathways.

Dosage and Administration Information

Furosemida Fecofar, which contains the active ingredient furosemide, is primarily used via the oral route as a tablet for maintenance therapy. The medicine is also available as a solution for oral use, or as an injection for intravenous (IV) or intramuscular (IM) administration when a rapid effect is required or if oral intake is impractical. Specialized subcutaneous forms also exist for certain non-acute contexts. Parenteral use (IV or IM) is intended to be short-term, and patients are typically converted to oral tablets as soon as their clinical status allows.


Standard Administration Patterns

The oral dosing regimen begins with a typical starting range of 20 mg to 80 mg for adult edema, taken as a single dose. Subsequent adjustments to increase the dose must be separated by 6 to 8 hours to safely gauge the diuretic response. The medication is frequently prescribed for once or twice daily use, or sometimes in cyclic patterns over a few days each week. Oral tablets may be taken with or without food. Administration is generally scheduled for the morning and early afternoon to prevent the diuretic action from disrupting sleep patterns.


Special Procedural Requirements

Specific instructions govern the proper handling and administration of the drug. For injection, the IV dose must be administered slowly, over a period of 1 to 2 minutes. Additionally, if a patient is taking sucralfate, Furosemide must be taken 2 hours before or 2 hours after the sucralfate dose to ensure appropriate absorption. For populations such as older adults, the starting dose should be cautiously lower than the standard adult range. Pediatric dosing is determined based on the patient's body weight.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Furosemida Fecofar

This section provides a factual summary of the formal studies and clinical trials that define the research base for Furosemide, the active ingredient in Furosemida Fecofar, without offering clinical interpretation or recommendations.


Evidence for Fluid Retention Associated with Heart Conditions (Congestive Heart Failure Edema)

Research examining Furosemide in conditions characterized by functional limitations, particularly fluid retention related to heart conditions, was conducted across various clinical settings. Studies often monitored outcomes related to systemic or functional imbalance, such as changes in body weight and physical discomfort associated with swelling. These trials frequently compare different delivery methods or compare Furosemide against other medications in the same class.

The findings describe patterns observed in the studies that show research highlights changes measured during the study period. Research examined Furosemide's association with measured changes in physical discomfort and symptoms of fluid retention over short observation periods. Data show patterns related to higher doses sometimes being observed in patients with more severe conditions.

Research is ongoing to characterize long-term outcomes, such as functional and clinical measures, where comparative evidence is often lacking or mixed, particularly when looking at large-scale observational data. Studies report how symptoms evolved in the observed populations, but the results apply only to the populations studied, and certainty remains low regarding the absolute long-term impact on functional and clinical measures.


Evidence for Fluid Retention in Liver Disease (Cirrhosis and Ascites)

Research explored Furosemide in conditions associated with volume imbalance, such as fluid retention and ascites related to chronic liver disease (cirrhosis). Studies focused on outcomes monitoring physiological strain or stress, including the rate of fluid loss, changes in body weight, and the monitoring of kidney function. Often, research has examined Furosemide in combination with other classes of diuretics to study the comparative diuretic response.

Findings indicate that the combination of Furosemide with a potassium-sparing diuretic was frequently utilized and observed in many studies examining fluid balance. Research highlights changes measured during the study period related to fluid balance and weight loss in patients with non-refractory ascites. For patients with refractory ascites, some research describes the use of higher-dose intravenous Furosemide, sometimes with saline solutions, and evidence contributes to understanding symptom patterns in this challenging group.

Key Studies & References

  1. Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis
  2. Management of Refractory Ascites in Cirrhosis (AASLD Clinical Pearl)
  3. Diagnosis and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome (Cleveland Clinic Journal of Medicine)
  4. Why do we use the combination of furosemide and spironolactone in the treatment of cirrhotic ascites? (AASLD)

Frequently Asked Questions (FAQ)

Common questions about Furosemida Fecofar (FAQ)

Q: What is the main difference between Furosemida and 'water pills'?

Furosemida’s active ingredient, Furosemide, is classified as a Loop Diuretic. This is a specific and potent subclass of drugs often referred to as 'water pills' or diuretics. This classification indicates that the medicine has a unique site of action within the kidney that leads to a characteristically strong and rapid effect on fluid removal.

Q: How quickly does Furosemida Fecofar start working after taking it?

According to official product information, the onset of diuresis, which is the start of increased urination, typically occurs within 30 to 60 minutes following the oral tablet dose. The primary diuretic effect of an oral dose is usually complete within 6 to 8 hours.

Q: Can Furosemida Fecofar affect my blood sugar levels?

Regulatory documents indicate that Furosemide may cause increases in blood glucose levels and can potentially alter glucose tolerance tests. This potential effect means that official information notes that blood glucose monitoring may be necessary for patients with pre-existing glucose issues.

Q: What are common things people misunderstand about how Furosemida Fecofar should be used?

Official boxed warnings emphasize that Furosemide is a potent diuretic. A key clarification from regulatory documents is that if the medicine is given in excessive amounts, it can lead to severe water and electrolyte depletion. Therefore, official documents describe that careful medical supervision is part of the established use conditions to manage this risk.

Q: Does Furosemida Fecofar have a 'sulfa' component?

Yes, Furosemide is categorized chemically as a sulfonamide-derivative drug. Regulatory warnings state that patients with a known allergy to sulfonamides, sometimes called 'sulfa drugs,' may show a cross-sensitivity to Furosemide.

Q: Is this medicine the same as the one known as Lasix?

The active ingredient in Furosemida Fecofar is Furosemide, which is the generic, non-proprietary name. Lasix is one of the original and widely recognized brand names under which Furosemide is marketed internationally.

Q: How is Furosemida Fecofar used to help manage high blood pressure?

In addition to treating edema (fluid retention), Furosemide tablets are indicated in adults for the treatment of hypertension (high blood pressure). Regulatory documents describe its use either alone or in combination with other blood pressure medications.

Q: What happens if I miss a scheduled dose of Furosemida Fecofar?

Official consumer advice suggests taking the dose as soon as it is remembered, unless it is already too late in the afternoon (e.g., after 4 PM). If it is late, official consumer advice describes skipping the missed dose and taking the next dose at the usual time. Official consumer advice also describes not taking a double dose to compensate for a forgotten one.

Q: Is Furosemida Fecofar safe for people with kidney problems?

Furosemide is indicated for edema associated with certain renal diseases. However, regulatory documents state it is strictly contraindicated in anuria (the inability to pass urine). If a patient with severe progressive renal disease experiences increasing kidney impairment during treatment, official information notes the drug should be discontinued.

Q: What are the signs that Furosemida Fecofar is causing dehydration?

Patients are advised to monitor for symptoms of excessive fluid or electrolyte loss, which are common adverse reactions. These symptoms can include dry mouth, excessive thirst, feelings of weakness, lethargy, and muscle pains or cramps.

Q: What is the evidence regarding Furosemida use in older adult populations?

Official guidance advises that dose selection for older adults should be cautious, generally starting at the low end of the dosing range. Official documentation notes that older adults may have increased susceptibility to complications from excessive diuresis, dehydration, and vascular issues.

Q: Does Furosemida Fecofar make you feel tired or fatigued?

Regulatory information lists symptoms such as weakness and lethargy (a lack of energy) as possible effects. These symptoms are recognized as signs of excessive fluid and electrolyte loss, which are listed as very common adverse reactions.

Q: How long do the effects of Furosemida Fecofar typically last?

The diuretic effect, meaning the period of increased fluid excretion, generally lasts for approximately 6 to 8 hours following an oral dose in healthy adults. This duration is described in official prescribing information.

Q: Are there any known issues with taking Furosemida Fecofar and alcohol consumption?

Yes, official documents note that the adverse reaction of orthostatic hypotension may occur, and this effect can be aggravated by consuming alcohol. Orthostatic hypotension is the feeling of dizziness or lightheadedness that can occur when standing up suddenly.

Q: Is Furosemida Fecofar a medicine that requires regular blood tests?

Official product information describes that monitoring serum electrolytes (such as potassium), CO2, creatinine, and BUN is expected to be frequent during the initial months of therapy and periodically afterward. This monitoring is necessary due to the medicine's potent effect on fluid and electrolyte balance.

Q: Can Furosemida Fecofar cause skin sensitivity to the sun?

Yes, regulatory documents list photosensitivity among the dermatologic-hypersensitivity adverse reactions. Official documentation describes that patients have been advised that their skin may become more sensitive to sunlight while taking this medicine.

Q: Are there different forms or strengths of Furosemida Fecofar available?

Furosemide, the active ingredient, is widely available as oral tablets, commonly in 20 mg, 40 mg, and 80 mg strengths, as noted in regulatory sources. It is also available as an oral solution and as an injectable solution for intravenous or intramuscular use.

Q: Is Furosemida Fecofar considered a high-alert medication by regulatory bodies?

Regulatory sources include a Boxed Warning for Furosemide, which is the most serious warning designated by the FDA. This warning explicitly states that the drug is potent and that excessive amounts can lead to severe water and electrolyte depletion, thus requiring careful medical supervision.

Q: What happens if Furosemida Fecofar is stopped suddenly?

Official consumer information states that discontinuing the drug abruptly is part of a patient's treatment plan that should be discussed with a prescriber. Discontinuing the drug may lead to the return of the symptoms or condition being treated, such as rising blood pressure or the return of edema.

Q: Is there a link between Furosemida Fecofar and changes in calcium levels?

Yes, regulatory documents state that Furosemide may cause a reduction in serum levels of calcium and magnesium. For this reason, the levels of these electrolytes are described as being monitored periodically during treatment.

Q: How does Furosemida Fecofar compare to other diuretics mentioned in regulatory texts?

Furosemide is classified as an agent where a greater diuretic potential is desired compared to other classes. For instance, the label notes that hypertensive patients whose condition cannot be adequately controlled with a thiazide diuretic will likely require combination therapy, or may not be adequately controlled with Furosemide alone.

Q: Is Furosemida Fecofar generally used for short-term or long-term management?

The injectable forms of the medicine are generally intended for short-term, acute use. However, for maintenance therapy, the oral tablets may be required for a long time, potentially for the rest of a patient’s life, depending on the underlying chronic condition being managed.

Q: What is the half-life of Furosemida as described in scientific literature?

According to official prescribing information, the terminal half-life of Furosemide in normal adults is approximately 2 hours. This duration can be extended, however, in the presence of conditions like congestive heart failure or severe kidney impairment.

Q: Are there any foods or drinks to avoid while taking Furosemida Fecofar?

Regulatory drug interactions specifically mention that consuming large quantities of Licorice is associated with an enhanced risk of potassium loss when combined with Furosemide. Otherwise, the oral tablets may generally be taken with or without food.

Q: What information is provided about Furosemida and its effect on blood pressure in the elderly?

Official geriatric use guidance highlights that older patients are more susceptible to excessive diuresis and the resulting volume reduction. This can lead to complications such as hypotension (low blood pressure) and vascular complications, which is why a lower starting dose is often described as being necessary.

Q: Why is my doctor checking my electrolytes while I take this drug?

Official documents describe that monitoring serum electrolytes frequently and periodically is necessary because Furosemide is a potent diuretic that actively modifies salt and water balance. This vigilance is required to identify potential electrolyte disturbances and serious conditions like hypovolemia early.

How should Furosemida Fecofar be stored and disposed of?

How to Store and Dispose of Furosemida Fecofar?

Furosemide tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). Storage must be managed to protect the tablets from light and excess moisture; the medicine must also be kept from freezing.

Container and Protection

The product must remain in its original container, which should be tightly closed and light-resistant. It is mandatory to store the medication in a secure location out of the sight and reach of children.

Disposal Instructions

Official guidance requires that unused or expired Furosemide tablets not be flushed down the toilet or disposed of in household trash. To ensure proper environmental protection, consult a pharmacist or use an authorized medicine take-back program for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Furosemida Fecofar found in:

A-Z Index: